T he discovery of bacterial CRISPR-Cas systems that prevent infection by bacterial viruses (phages) has opened a paradigm for bacterial immunity while yielding exciting tools for targeted genome editing. CRISPR systems destroy phage genomes, and in turn, phages express anti-CRISPR (Acr) proteins that directly inhibit Cas effectors (1, 2) . Six distinct types (I to VI) of CRISPR systems are spread widely across the bacterial world (3), but Acr proteins have only been discovered for type I and II CRISPR systems (1, (3) (4) (5) (6) . Given the prevalence and diversity of CRISPR systems, we predict that Acr proteins against other types await discovery.
Acr proteins do not have conserved sequences or structures and only share their relatively small size, making de novo prediction of acr function challenging (6) . However, acr genes often cluster together with other acr genes or are adjacent to highly conserved Acr-associated genes (aca genes) in "acr loci" (7, 8) . In this work, we sought to identify acr genes in bacteria and phages that are not homologous to previously identified acr or aca genes.
Acr proteins were first discovered in Pseudomonas aeruginosa, inhibiting type I-F and I-E CRISPR systems (1, 9) . P. aeruginosa strains also encode a third CRISPR subtype (type I-C), which lacks known inhibitors (10). We engineered P. aeruginosa to target phage JBD30 with type I-C CRISPRCas ( fig. S1A ) and used it in parallel with existing type I-E (strain SMC4386) and I-F (strain PA14) CRISPR strains to screen for additional acr candidates.
Homologs of aca1 were searched for in Pseudomonas genomes, and seven gene families not previously tested for Acr function were identified upstream of aca1 (Fig. 1A) . Three genes inhibited the type I-E CRISPR-Cas system (acrIE5-7), one inhibited type I-F (acrIF11), restoring the plaquing of a targeted phage, and two genes had no inhibitory activity (orf1 and orf2) (Fig. 1B, fig.  S1B , and tables S1 and S2). Another gene exhibited dual I-E and I-F inhibition, and domain analysis revealed a chimera of previously identified acrIE4 and acrIF7 (acrIE4-F7). No type I-C inhibitors were identified. The type I-F inhibitor acrIF11 was commonly represented in both the P. aeruginosa mobilome and in more than 50 species of diverse Proteobacteria ( fig. S2 and table S2). acrIF11 is often associated with genes that encode DNA-binding motifs, which we have designated aca4 to aca7 ( fig. S2 and tables S1, S3, and S4). To confirm that these aca genes can be used to facilitate acr discovery, we used aca4 to discover an additional Pseudomonas Acr, acrIF12 (Fig. 1, A and B) .
Given the widespread nature of acrIF11, we next used it to discover Acr proteins against CRISPR systems in which they have not yet been found: type I-C, a minimal class 1 system, and type V-A CRISPR-Cas12a (Cpf1), a class 2 single effector system that has high efficiency in genome editing (11) (12) (13) . To find AcrIC and AcrVA proteins, we first searched for genomes that encode CRISPR spacers that match a target protospacer elsewhere in the same genome ( Fig. 2A) . The tolerance of this "self-targeting" in viable bacteria indicates potential inhibition of the CRISPR system (4) because genome cleavage would result in bacterial death.
The Gram-negative bovine pathogen Moraxella bovoculi (14, 15) is a Cas12a-containing organism (11) in which four of the seven genomes feature type V-A self-targeting (table S5) , and one strain (58069) also features self-targeting by type I-C (table S6). Although no previously described acr or aca genes were present in this strain, an acrIF11 homolog was found in phages that infect the human pathogen Moraxella catarrhalis (16), a close relative of M. bovoculi. Genes adjacent to acrIF11 in M. catarrhalis had homologs in the self-targeting M. bovoculi strains (Fig. 2B ), and together, these genes were selected as candidate acr genes. Each gene was first tested against the type I-C and I-F systems introduced above because both subtypes are found in Moraxella. Gene AAX09_07415 (now acrIC1) inhibited the type I-C system, explaining the tolerance of self-targeting Gene modification assessed by means of T7E1 assay 72 hours after transfection; error bars indicate SEM for n = 3 independent biological replicates.
in strain 58069 (Fig. 2C) . Additionally, gene E9U_08473 (acrIF13) from the M. catarrhalis BC8 prophage completely inhibited I-F function, as did AKI27193.1 (acrIF14), which is found in phage Mcat5 at the same genomic position as that of acrIF11 in BC8 (Fig. 2, B and D) . These Acr proteins possess broad spectrum activity; the type I-C and I-F systems in Moraxella and Pseudomonas only share an average pairwise identity of 30 and 36%, respectively ( fig. S3 ) Because of the limited tools available for the genetic manipulation of Moraxella sp., the remaining genes were tested for type V-A Acr function in P. aeruginosa PAO1 engineered to express MbCas12a and a CRISPR-RNA (crRNA) that targets P. aeruginosa phage JBD30. Two distinct crRNAs were used, showing strong reduction of titer by more than four orders of magnitude (Fig. 2E) . The first gene in the M. bovoculi 58069 acr locus, AAX09_07405 (acrVA1), restored phage titers nearly to levels seen with the crRNA-minus control, indicating that it robustly inhibits Cas12a. This is in good agreement with the independent discovery of AcrVA1 reported in a companion paper (17) . The adjacent gene, acrVA2, also inhibited targeting, as did its ortholog (acrVA2.1) (Fig. 2E ). An additional gene from this locus, acrVA3, possessed subtle anti-Cas12a activity but was toxic to cells and adversely affected JBD30 phage growth independently of Cas12a ( fig. S5) . We therefore tested an ortholog with 43% sequence identity, B0181_04965 (acrVA3.1), which showed stronger Cas12a inhibition with no toxicity or adverse effects on phage growth (Fig. 2E and fig. S5 ). Surprisingly, acrVA3.1 also showed partial restoration of phage titer during type I-C targeting, suggesting that it may inhibit the type I-C as well as type V-A system (Fig. 2, C and E) . Although these two CRISPR subtypes do not share any protein components, a dual-specificity inhibitor may use distinct protein-interaction interfaces or modulate an undiscovered host process required for CRISPR immunity. We used the Acr "key" acrIF11 to unlock acr loci that encode seven distinct acr genes inhibiting type I-C, I-F, and V-A CRISPR. Below, we focus on the evolutionary analysis of type V-A inhibitors and their function in mammalian cells.
The gene acrVA1 encodes a 170-amino acid protein found only in Moraxella sp. and Eubacterium eligens ( fig. S6 ), both type V-A CRISPR-containing organisms. By contrast, acrVA2 (322 amino acids) and acrVA3 (168 amino acids) orthologs are found broadly distributed throughout multiple classes of bacteria. For example, acrVA2 orthologs are present in Lachnospiraceae and Leptospira ( fig.  S7 ), which contain type V-A CRISPR, as well as in Moraxella, Leptospira, and Lactobacillus phages. Distant orthologs of acrVA2 were also identified on plasmids and conjugative elements in Escherichia coli ( fig. S7 ), although the importance of a bacterium that lacks type V-A CRISPR encoding a putative acrVA gene is unknown. Orthologs of acrVA3 were identified in many Proteobacteria and in Eubacterium and Clostridium species, which encode type V-A CRISPR ( fig. S8) .
Given the inhibitory effect of acrVA1-3.1 on MbCas12a in bacteria, we sought to determine whether AcrVA proteins could block MbCas12a activity in human cells. Human U2-OS-enhanced green fluorescent protein (EGFP) cells (18) transiently expressing MbCas12a, EGFP-targeting crRNA, and human codon-optimized acrVA1-3.1 were assessed for EGFP disruption by using flow cytometry. Coexpression of MbCas12a and crRNA resulted in~60 to 70% disruption of EGFP expression relative to background (Fig. 3A) . AcrVA1 expression reduced EGFP disruption to background levels, indicating inhibition of MbCas12a, whereas the other acrVA genes showed little evidence of activity here (Fig. 3A) . We additionally found that acrVA1 inhibited another Cas12a ortholog (Mb3Cas12a) while having no impact on SpyCas9 editing in the same assay (Fig. 3B) . Titration of the Acr plasmid relative to the Cas12a expression plasmid revealed comparable dose-dependent responses to inhibition between MbCas12a or Mb3Cas12a with AcrVA1 and SpyCas9 with AcrIIA4 ( fig. S9 ). Furthermore, AcrVA1 was found to be a broad-spectrum inhibitor of other commonly used Cas12a orthologs (11), providing strong inhibition of AsCas12a and LbCas12a and modest inhibition of FnCas12a (Fig. 3C) .
Last, to determine whether AcrVA1 could inhibit Cas12a-mediated modification of endogenous loci in human cells, U2-OS cells were cotransfected with plasmids expressing acrVA1, Cas12a, and crRNAs that target endogenous genes (RUNX1, DNMT1, or FANCF) and assessed for gene disruption by means of T7 endonuclease I (T7E1) assay. We found that AcrVA1 completely inhibited gene disruption by MbCas12a and Mb3Cas12a, with modest to strong inhibition of As-, Lb-, and FnCas12a orthologs (Fig. 3D and fig. S10 ).
Here, we report the discovery of a broadly distributed type I-F Acr protein (AcrIF11) that served as a marker for acr loci and led to the identification of type I-C and V-A CRISPR inhibitors. One of these acrVA genes (acrVA1) potently inhibits Cas12a in bacteria and in human cells, providing a new tool for Cas12a regulation. Our findings show that mobile genetic elements can tolerate bacteria with more than one CRISPR-Cas type by possessing multiple Acr proteins in the same locus. The strategy described here enabled the identification of many widespread Acr proteins, which may prove useful in future Acr discovery.
